ArticleTargeted oncology2019

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.

Sung-Bae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.